This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 2 of 2 for:    retinitis pigmentosa jcyte

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by jCyte, Inc
Information provided by (Responsible Party):
jCyte, Inc Identifier:
First received: March 2, 2017
Last updated: April 18, 2017
Last verified: April 2017
This study evaluates the changes in visual function at 12 months following a single injection of human retinal progenitor cells compared to untreated controls in a cohort of adult subjects with RP.

Condition Intervention Phase
Retinitis Pigmentosa Biological: human retinal progenitor cells Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)

Resource links provided by NLM:

Further study details as provided by jCyte, Inc:

Primary Outcome Measures:
  • effect of treatment on ocular function [ Time Frame: 12 months ]
    assessed by full field sensitivity threshold

Secondary Outcome Measures:
  • effect of treatment on ocular function [ Time Frame: 12 months ]
    assessed by visual acuity

  • effect of treatment on ocular function [ Time Frame: 12 months ]
    assessed by mobility testing

  • effect of treatment on functional vision [ Time Frame: 12 months ]
    assessed by visual quality of life evaluation

  • effect of treatment on ocular function [ Time Frame: 12 months ]
    assessed by Goldmann visual field area

  • safety of intravitreal injection of hRPC [ Time Frame: 12 months ]
    assessed by treatment emergent adverse events, immunogenicity and safety visual assessments

Estimated Enrollment: 70
Actual Study Start Date: March 1, 2017
Estimated Study Completion Date: January 2021
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Test (jCell injection)
single intravitreal injection of 1.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
Biological: human retinal progenitor cells
live suspension of 1.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
Other Name: jCell
No Intervention: Untreated Control
no treatment, the eye with the poorest vision in each Control subject will be documented and designated as the "study eye" for the purposes of endpoint analysis

Detailed Description:
There is no effective treatment for RP; once photoreceptors are lost, they do not regenerate. The rate of deterioration of vision varies from person to person, with most people with RP legally blind by age 40. Preclinical studies demonstrated that transplantation of retinal progenitor cells into the eye can result in both photoreceptor replacement and significant slowing of host photoreceptor loss. Thus, the primary goal of this therapy is to preserve, and potentially improve, vision by intervening in the disease at a time when dystrophic host photoreceptors can be protected and reactivated. Based on the demonstration of acceptable safety and tolerability in a phase 1/2a study, this phase 2b study is designed as a controlled comparison of the changes in visual function and functional vision in subjects who receive a single jCell injection in comparison to a comparable untreated control group of subjects with RP.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Clinical diagnosis of RP confirmed by ERG and willing to consent to mutation typing, if not already done Best corrected visual acuity (BCVA) 20/40 or worse and no worse than 20/1000 Adequate organ function and negative infectious disease screen Female of childbearing potential must have negative pregnancy test and be willing to use medically accepted methods of contraception throughout the study

Exclusion Criteria:

Eye disease other than RP that impairs visual function Pseudo-RP, cancer-associated retinopathies History of malignancy or other end-stage organ disease, or any chronic disease requiring continuous treatment with system steroids, anticoagulants or immunosuppressive agents Known allergy to penicillin or streptomycin Treatment with corticosteroids or any investigational or neuroprotectant therapy within 90 days of enrollment Cataract surgery within 3 months prior to enrollment

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03073733

Contact: Jesi Zavala 714-509-2151

United States, California
Gavin Herbert Eye Inst, Univ Cal Irvine Not yet recruiting
Irvine, California, United States, 92697
Principal Investigator: Baruch Kuppermann, MD         
Retina-Vitreous Associates Medical Group Recruiting
Los Angeles, California, United States, 90074
Contact: Janet Kurokouchi    310-289-2478 ext 123   
Principal Investigator: David Boyer, MD         
Sponsors and Collaborators
jCyte, Inc
  More Information

Responsible Party: jCyte, Inc Identifier: NCT03073733     History of Changes
Other Study ID Numbers: JC-02
Study First Received: March 2, 2017
Last Updated: April 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn processed this record on July 26, 2017